

Application No:10/507,272; Docket No: 10500-008
Amdt. dated July 27, 2006
Reply to Office action of March 27, 2006

RECEIVED
CENTRAL FAX CENTER
JUL 27 2006

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-15 (cancelled).

16. (currently amended) A method of treatment of a state comprising preparing an angiogenesis promoting medicament comprising use of type 1 Placental Growth Factor (PLGF-1) comprising preparing a medicament that comprises PLGF-1 as an active principle, and administering said medicament to treat the state, the wherein said medicament promotes angiogenesis in the treatment of a state selected from the group consisting of:

- diseases and pathological alterations involving the cutaneous or subcutaneous connective tissue,
- scleroderma, and
- early skin aging due to exposure to atmospheric aggressive agents or to protracted solar irradiation.

17. (currently amended) The method ~~of use~~ according to claim 16, wherein the state is selected from the group consisting of localized scleroderma and progressive systemic scleroderma.

18. (currently amended) The method ~~of use~~ according to claim 17, wherein the localized scleroderma is cutaneous scleroderma and the progressive systemic scleroderma is myocardial scleroderma.

19. (currently amended) The method ~~of use~~ according to claim 16, wherein the state is for treatment of a pathological loss of hair due to a particular state selected from the group consisting of alopecia, hormonal disorders, chemotherapy, radiotherapy and administration of medicine.

Application No:10/507,272; Docket No: 10500-008
Amdt. dated July 27, 2006
Reply to Office action of March 27, 2006

20. (currently amended) The method ~~of use~~ according to claim 16, wherein the medicament is in a form suitable for generating a local or systemic effect.

21. (currently amended) The method ~~of use~~ according to claim 16, wherein the medicament is in a form suitable for endovenous, intramuscular, intrarticular, subcutaneous or topical administration or subcutaneous implant or ionophoresis.

22. (currently amended) The method ~~of use~~ according to claim 19, wherein the medicament is in a form suitable for endovenous, intramuscular, intrarticular, subcutaneous or topical administration or subcutaneous implant or ionophoresis.

23. (currently amended) A method of cosmetic treatment of a state of use of type 1 ~~Placental Growth Factor (PLGF-1)~~ comprising administering to adult individuals type 1 ~~Placental Growth Factor (PLGF-1)~~ to promote cutaneous or subcutaneous angiogenesis, wherein the state is in the prevention and cosmetic treatment of natural skin aging.

24. (currently amended) A method of cosmetic treatment of a state use of type 1 ~~Placental Growth Factor (PLGF-1)~~ comprising administering to adult individuals type 1 ~~Placental Growth Factor (PLGF-1)~~ to promote perifollicular angiogenesis, wherein the state is in the prevention and in the cosmetic treatment of the natural loss of hair.

25. (currently amended) The method ~~of use~~ according to claim 23, wherein the PLGF-1 is formulated in a cosmetic composition for topical administration.

26. (currently amended) The method ~~of use~~ according to claim 24, wherein the PLGF-1 is formulated in a cosmetic composition for topical administration.

27. (currently amended) The method ~~of use~~ according to claim 16, wherein PLGF-1 is comprised in an amount suitable for an administration of 1 to 500 µg per Kg of body per day, preferably of 10 µg/Kg/day to 200 µg/Kg/day.

Application No:10/507,272; Docket No: 10500-008
Amdt. dated July 27, 2006
Reply to Office action of March 27, 2006

28. (currently amended) The method ~~of use~~ according to claim 23, wherein PLGF-1 is comprised in an amount suitable for an administration of 1 to 500 μg per Kg of body per day, preferably of 10 $\mu\text{g}/\text{Kg}/\text{day}$ to 200 $\mu\text{g}/\text{Kg}/\text{day}$.

29. (currently amended) The method ~~of use~~ according to claim 24, wherein PLGF-1 is comprised in an amount suitable for an administration of 1 to 500 μg per Kg of body per day, preferably of 10 $\mu\text{g}/\text{Kg}/\text{day}$ to 200 $\mu\text{g}/\text{Kg}/\text{day}$.

30. (currently amended) A ~~pharmaceutical~~ topical composition comprising type 1 Placental Growth Factor (PLGF-1) as active principle and a pharmaceutically acceptable excipient, wherein at least 98.5% of the PLGF-1 is in active dimeric and multimeric form, at least 70% is in dimeric form and no more than 1.5% is in monomeric form, and wherein PLGF-1 is comprised ~~in an amount from 50 μg to 30 mg per unitary dose for parenteral use and in an amount from 0.1 mg to 10 mg per gram of said pharmaceutical~~ topical ~~composition for topical use.~~

31. (currently amended) A ~~cosmetic~~ topical composition comprising type 1 Placental Growth Factor (PLGF-1) as active principle and a cosmetically acceptable excipient, wherein at least 98.5% of the PLGF-1 is in active dimeric and multimeric form, at least 70% is in dimeric form and no more than 1.5% is in monomeric form, and wherein PLGF-1 is comprised in an amount from 0.01 mg to 0.09 mg per gram of said ~~cosmetic~~ topical composition.

32. (previously presented) The composition according to claim 30, in a form selected from the group consisting of a solution, a lotion, a W/O emulsion, an O/W emulsion, a suspension, a liposome suspension, a gel, a cream, a paste, an ointment and a subcutaneous implant.

33. (previously presented) The composition according to claim 31, in a form selected from the group consisting of a solution, a lotion, a W/O emulsion, an O/W emulsion, a suspension, a liposome suspension, a gel, a cream, a paste, an ointment and a subcutaneous

Application No:10/507,272; Docker No: 10500-008
Amdt. dated July 27, 2006
Reply to Office action of March 27, 2006

implant.

34. (previously presented) The composition according to claim 30, additionally comprising one or more substances capable of stabilizing the PLGF-1 in the active dimeric-multimeric forms.

35. (previously presented) The composition according to claim 31, additionally comprising one or more substances capable of stabilizing the PLGF-1 in the active dimeric-multimeric forms.